Sanofi SA (ADR) news

   Watch this stock
Showing stories 1 - 10 of about 174   

Articles published

SNY 42.63 +0.03 (0.07%)
price chart
Sanofi SA (ADR) and Diabetes: Things Are Not Working Out
Sanofi SA (NYSE:SNY) came into the spotlight after Food and Drug Administration (FDA) initiated a debate in association with its Diabetes Mellitus Type II combo drug LixiLan pointing out number of questions regarding the safety and clinical efficacy ...
Sanofi's LixiLan Faces Scrutiny From FDA  Bidness ETC
HC Stocks Indications: Baxter International Inc (NYSE:BAX), Sanofi SA (ADR ...
Shares of Baxter International Inc (NYSE:BAX) ended Thursday session in red amid volatile trading. The shares closed down -0.10 points or -0.21% at $48.22 with 3.78 million shares getting traded.
Sanofi SA (ADR) (SNY) Confirmed Confidentiality Agreement with Medivation Inc ...
As Medivation Inc (NASDAQ:MDVN) is headed towards a selloff, it is in talks with many parties who seek to buy the company. With Board of Directors consent, Medivation and Sanofi SA (ADR) (NYSE:SNY) have entered into confidentiality agreement.
Medivation Bidders Will Have To Price In Talazoparib; BMO Sees $68-$76 ...  Benzinga
HC Stocks Overview: Medtronic PLC (NYSE:MDT), Sanofi SA (ADR) (NYSE:SNY)
Shares of Medtronic PLC (NYSE:MDT) ended Tuesday session in green amid volatile trading. The shares closed up +1.33 points or 1.53% at $88.25 with 4.56 million shares getting traded.
Sanofi SA (ADR) - DICE Deal To Replace Injectables With Oral Formulations
Sanofi SA (ADR) (NYSE:SNY) has announced it has signed an agreement with DiCE Molecules, for the research and development of novel molecules that can replace injectables with oral formulations, for certain diseases.
Sanofi and DICE on a Research Venture to Replace Injections with New Drugs  Bidness ETC
Sanofi SA (ADR) (NYSE:SNY) Looking To Acquire Medivation Inc (NASDAQ:MDVN) For ...
Sanofi SA (ADR) (NYSE:SNY) has made public its intention of acquiring Medivation Inc (NASDAQ:MDVN), having tabled a $9.3 billion takeover bid.
Sanofi Turns Hostile, Makes $9.3 Billion Bid for Medivation: A Smart Move?  Bidness ETC
Why Medivation Will Likely Reject Sanofi's $52.50/Share Buyout Offer  Benzinga
Who Will Acquire Medivation Inc; Sanofi SA (ADR), Gilead Sciences, Inc. or Others?
On the other hand, Sanofi SA (NYSE:SNY) is also working with the financial advisers for a possible acquisition of the Medivation.
Medivation Surges On Reported Pushback Of Sanofi Takeover Effort  Benzinga
M&A Buzz Sets Medivation Inc (MDVN) Options Pits on Fire  Schaeffers Research (blog)
Pfizer Inc, Sanofi SA (ADR), Novartis AG (ADR): Who Will Acquire Medivation Inc?
The drugmakers are looking for M&A to expand their drug portfolios in order to make their drug pipeline more robust and competitive.
Medivation Inc Acquisition: Sanofi SA (ADR) Won't Take No for an Answer  Bidness ETC
If Medivation Is Sold, Brean Thinks It'll Be For Far More Than Sanofi ...  Benzinga
How Analysts Rated Sanofi SA (ADR) (NYSE:SNY) Last Week?
Out of 5 analysts covering Sanofi-aventis Sa (NYSE:SNY), 2 rate it a “Buy”, 1 “Sell”, while 2 “Hold”. This means 40% are positive.
Sanofi SA (ADR), Medivation Inc: Journey to Possible Hostile Takeover Begins
Sanofi SA (ADR) (NYSE:SNY) is all set to move forward with its proposal to oust Medivation board following the latter's refusal to accept its unsolicited $9.3 billion acquisition offer.
Sanofi ADRs Slip 3%; Says Bid For Medivation Offers Highest 'Transaction ...  Sonoran Weekly Review